Cargando…
6-(Tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as Novel Potent CK2 Inhibitors
In this work, we describe the design, synthesis, and structure-activity relationship of 6-(tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as inhibitors of Casein kinase 2 (CK2). At first, we optimized the reaction conditions for the azide-nitrile cycloaddition in the series of 6-cyano-7-aminoazolopyr...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783892/ https://www.ncbi.nlm.nih.gov/pubmed/36557833 http://dx.doi.org/10.3390/molecules27248697 |
_version_ | 1784857681732829184 |
---|---|
author | Urakov, Grigoriy V. Savateev, Konstantin V. Kotovskaya, Svetlana K. Rusinov, Vladimir L. Spasov, Alexandr A. Babkov, Denis A. Sokolova, Elena V. |
author_facet | Urakov, Grigoriy V. Savateev, Konstantin V. Kotovskaya, Svetlana K. Rusinov, Vladimir L. Spasov, Alexandr A. Babkov, Denis A. Sokolova, Elena V. |
author_sort | Urakov, Grigoriy V. |
collection | PubMed |
description | In this work, we describe the design, synthesis, and structure-activity relationship of 6-(tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as inhibitors of Casein kinase 2 (CK2). At first, we optimized the reaction conditions for the azide-nitrile cycloaddition in the series of 6-cyano-7-aminoazolopyridimines and sodium azide. The regioselectivity of this process has been shown, as the cyano group of the pyrimidine cycle was converted to tetrazole while the nitrile of the azole fragment did not react. The desired tetrazolyl-azolopyrimidines were obtained in a moderate to excellent yields (42–95%) and converted further to water soluble sodium salts by the action of sodium bicarbonate. The obtained 6-(tetrazol-5-yl)-7-aminopyrazolo[1,5-a]pyrimidines 2a–k and their sodium salts 3a–c, 3g–k showed nano to low micromolar range of CK2 inhibition while corresponding [1,2,4]triazolopyrimidines 10a–k were less active (IC(50) > 10 µM). The leader compound 3-phenyl-6-(tetrazol-5-yl)-7-aminopyrazolo[1,5-a]pyrimidine 2i as CK2 inhibitor showed IC(50) 45 nM. |
format | Online Article Text |
id | pubmed-9783892 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97838922022-12-24 6-(Tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as Novel Potent CK2 Inhibitors Urakov, Grigoriy V. Savateev, Konstantin V. Kotovskaya, Svetlana K. Rusinov, Vladimir L. Spasov, Alexandr A. Babkov, Denis A. Sokolova, Elena V. Molecules Article In this work, we describe the design, synthesis, and structure-activity relationship of 6-(tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as inhibitors of Casein kinase 2 (CK2). At first, we optimized the reaction conditions for the azide-nitrile cycloaddition in the series of 6-cyano-7-aminoazolopyridimines and sodium azide. The regioselectivity of this process has been shown, as the cyano group of the pyrimidine cycle was converted to tetrazole while the nitrile of the azole fragment did not react. The desired tetrazolyl-azolopyrimidines were obtained in a moderate to excellent yields (42–95%) and converted further to water soluble sodium salts by the action of sodium bicarbonate. The obtained 6-(tetrazol-5-yl)-7-aminopyrazolo[1,5-a]pyrimidines 2a–k and their sodium salts 3a–c, 3g–k showed nano to low micromolar range of CK2 inhibition while corresponding [1,2,4]triazolopyrimidines 10a–k were less active (IC(50) > 10 µM). The leader compound 3-phenyl-6-(tetrazol-5-yl)-7-aminopyrazolo[1,5-a]pyrimidine 2i as CK2 inhibitor showed IC(50) 45 nM. MDPI 2022-12-08 /pmc/articles/PMC9783892/ /pubmed/36557833 http://dx.doi.org/10.3390/molecules27248697 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Urakov, Grigoriy V. Savateev, Konstantin V. Kotovskaya, Svetlana K. Rusinov, Vladimir L. Spasov, Alexandr A. Babkov, Denis A. Sokolova, Elena V. 6-(Tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as Novel Potent CK2 Inhibitors |
title | 6-(Tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as Novel Potent CK2 Inhibitors |
title_full | 6-(Tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as Novel Potent CK2 Inhibitors |
title_fullStr | 6-(Tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as Novel Potent CK2 Inhibitors |
title_full_unstemmed | 6-(Tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as Novel Potent CK2 Inhibitors |
title_short | 6-(Tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as Novel Potent CK2 Inhibitors |
title_sort | 6-(tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as novel potent ck2 inhibitors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783892/ https://www.ncbi.nlm.nih.gov/pubmed/36557833 http://dx.doi.org/10.3390/molecules27248697 |
work_keys_str_mv | AT urakovgrigoriyv 6tetrazol5yl7aminoazolo15apyrimidinesasnovelpotentck2inhibitors AT savateevkonstantinv 6tetrazol5yl7aminoazolo15apyrimidinesasnovelpotentck2inhibitors AT kotovskayasvetlanak 6tetrazol5yl7aminoazolo15apyrimidinesasnovelpotentck2inhibitors AT rusinovvladimirl 6tetrazol5yl7aminoazolo15apyrimidinesasnovelpotentck2inhibitors AT spasovalexandra 6tetrazol5yl7aminoazolo15apyrimidinesasnovelpotentck2inhibitors AT babkovdenisa 6tetrazol5yl7aminoazolo15apyrimidinesasnovelpotentck2inhibitors AT sokolovaelenav 6tetrazol5yl7aminoazolo15apyrimidinesasnovelpotentck2inhibitors |